When these deletions were introduced using CRISPR-Cas9 within the APP of APP-KI mice (an animal model of AD), they significantly reduced Aβ pathology, which in these mice is driven by three human mutations within the mouse APP gene [49]. The gene discussed is APP; the disease is Alzheimer disease.